Considering the time limitation for hindering the possibility of metastasis, it appears that vaccination strategies, such as immunization against NY-SAR-35 antigen in patients who exhibit high expression levels of the target antigen in the primary tumor, have promising potential as a method to pursue following an initial cancer diagnosis. This evidence concerns the gene FMR1NB and cancer.